These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 25888551)

  • 21. Experimental modeling of preclinical and clinical stages of Parkinson's disease.
    Khaindrava VG; Kozina EA; Kudrin VS; Kucheryanu VG; Klodt PD; Narkevich VB; Bocharov EV; Nanaev AK; Kryzhanovsky GN; Raevskii KS; Ugrumov MV
    Bull Exp Biol Med; 2011 Mar; 150(5):566-9. PubMed ID: 22235385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ventricular dilatation and brain atrophy in patients with Parkinson's disease with incipient dementia.
    Camicioli R; Sabino J; Gee M; Bouchard T; Fisher N; Hanstock C; Emery D; Martin WR
    Mov Disord; 2011 Jul; 26(8):1443-50. PubMed ID: 21442661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathological basis for dementia in elderly patients with idiopathic Parkinson's disease.
    Yoshimura M
    Eur Neurol; 1988; 28 Suppl 1():29-35. PubMed ID: 3378559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer's and Parkinson's disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia.
    Chan-Palay V
    J Comp Neurol; 1988 Jul; 273(4):543-57. PubMed ID: 2463283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive deficits in Parkinson's disease: a cognitive neuroscience perspective.
    Robbins TW; Cools R
    Mov Disord; 2014 Apr; 29(5):597-607. PubMed ID: 24757109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease.
    Müller ML; Albin RL; Kotagal V; Koeppe RA; Scott PJ; Frey KA; Bohnen NI
    Brain; 2013 Nov; 136(Pt 11):3282-9. PubMed ID: 24056537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort.
    Williams-Gray CH; Evans JR; Goris A; Foltynie T; Ban M; Robbins TW; Brayne C; Kolachana BS; Weinberger DR; Sawcer SJ; Barker RA
    Brain; 2009 Nov; 132(Pt 11):2958-69. PubMed ID: 19812213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options.
    Williams-Gray CH; Foltynie T; Lewis SJ; Barker RA
    CNS Drugs; 2006; 20(6):477-505. PubMed ID: 16734499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroimaging of brain changes associated with cognitive impairment in Parkinson's disease.
    Christopher L; Strafella AP
    J Neuropsychol; 2013 Sep; 7(2):225-40. PubMed ID: 23551844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What causes mental dysfunction in Parkinson's disease?
    Emre M
    Mov Disord; 2003 Sep; 18 Suppl 6():S63-71. PubMed ID: 14502658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholinergic dysfunction contributes to gait disturbance in early Parkinson's disease.
    Rochester L; Yarnall AJ; Baker MR; David RV; Lord S; Galna B; Burn DJ
    Brain; 2012 Sep; 135(Pt 9):2779-88. PubMed ID: 22961550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway.
    Jellinger KA
    Mol Chem Neuropathol; 1991 Jun; 14(3):153-97. PubMed ID: 1958262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dementia in Parkinson's disease: cause and treatment.
    Emre M
    Curr Opin Neurol; 2004 Aug; 17(4):399-404. PubMed ID: 15247534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits?
    Helmich RC; Hallett M; Deuschl G; Toni I; Bloem BR
    Brain; 2012 Nov; 135(Pt 11):3206-26. PubMed ID: 22382359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations.
    Goldman JG; Stebbins GT; Dinh V; Bernard B; Merkitch D; deToledo-Morrell L; Goetz CG
    Brain; 2014 Mar; 137(Pt 3):849-59. PubMed ID: 24480486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mild Cognitive Impairment in Parkinson's Disease-What Is It?
    Weil RS; Costantini AA; Schrag AE
    Curr Neurol Neurosci Rep; 2018 Mar; 18(4):17. PubMed ID: 29525906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dementia associated with Parkinson's disease.
    Emre M
    Lancet Neurol; 2003 Apr; 2(4):229-37. PubMed ID: 12849211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct alterations in Parkinson's medication-state and disease-state connectivity.
    Ng B; Varoquaux G; Poline JB; Thirion B; Greicius MD; Poston KL
    Neuroimage Clin; 2017; 16():575-585. PubMed ID: 28971008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Research in motion: the enigma of Parkinson's disease pathology spread.
    Brundin P; Li JY; Holton JL; Lindvall O; Revesz T
    Nat Rev Neurosci; 2008 Oct; 9(10):741-5. PubMed ID: 18769444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.